BR9611255A - ácido nucleico, processos para determinar a suscetibilidade de um paciente a câncer, para diagnosticar câncer em um paciente, para prever as perspectivas relativas do surgimento particular de um câncer em um paciente, para tratar câncer e para determinar a perda de heterozigosidade em amostra de tecido, sistema para detectar a presença ou ausência de, ou mutação, na região de cromossomo 10 humano, polipeptídeo, molécula e uso de ácido nucleico e de uma molécula. - Google Patents

ácido nucleico, processos para determinar a suscetibilidade de um paciente a câncer, para diagnosticar câncer em um paciente, para prever as perspectivas relativas do surgimento particular de um câncer em um paciente, para tratar câncer e para determinar a perda de heterozigosidade em amostra de tecido, sistema para detectar a presença ou ausência de, ou mutação, na região de cromossomo 10 humano, polipeptídeo, molécula e uso de ácido nucleico e de uma molécula.

Info

Publication number
BR9611255A
BR9611255A BR9611255-7A BR9611255A BR9611255A BR 9611255 A BR9611255 A BR 9611255A BR 9611255 A BR9611255 A BR 9611255A BR 9611255 A BR9611255 A BR 9611255A
Authority
BR
Brazil
Prior art keywords
cancer
patient
nucleic acid
determining
molecule
Prior art date
Application number
BR9611255-7A
Other languages
English (en)
Inventor
Nigel Kay Spurr
Ian Christopher Gray
Original Assignee
Imp Cancer Research Thecnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp Cancer Research Thecnology filed Critical Imp Cancer Research Thecnology
Publication of BR9611255A publication Critical patent/BR9611255A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"áCIDO NUCLEICO, PROCESSOS PARA DETERMINAR A SUSCETIBLIDADE DE UM PACIENTE A CâNCER, PARA DIAGNOSTICAR CâNCER EM UM PACIENTE, PARA PREVER AS PERSPECTIVAS RELATIVAS DO SURGIMENTO PARTICULAR DE UM CâNCER EM UM PACIENTE, PARA TRATAR CâNCER E PARA DETERMINAR A PERDA DE HETEROZIGOSIDADE EM AMOSTRA DE TECIDO, SISTEMA PARA DETECTAR A PRESENçA OU AUSêNCIA DE, OU MUTAçãO, NA REGIãO DE CROMOSSOMO 10 HUMANO, POLIPEPTìDEO, MOLéCULA E USO DE áCIDO NUCLEICO E DE UMA MOLéCULA". Processo para determinar a suscetibilidade de um paciente a câncer compreendendo as etapas de (i) obter uma amostra contendo ácido nucléico derivado do paciente, e (ii) contatar o referido ácido nucléico com um ácido nucléico capaz de seletivamente hibridizar para a região de cromossomo 10 humano, cuja região é ligada por DNA definido pelos marcadores de D10S541 e D10S215. Um ácido nucléico capaz de seletivamente hibridizar para a região de cromossomos 10 humano cuja região é ligada por DNA definido pelos marcadores de D10S541 e D10S215, desde que o ácido nucléico não seja qualquer um de alguns YACs, BACs, PACs ou ESTs, definidos aqui. Preferivelmente, o referido ácido nucléico é um gene supressor de tumor da próstata.
BR9611255-7A 1995-10-23 1996-10-22 ácido nucleico, processos para determinar a suscetibilidade de um paciente a câncer, para diagnosticar câncer em um paciente, para prever as perspectivas relativas do surgimento particular de um câncer em um paciente, para tratar câncer e para determinar a perda de heterozigosidade em amostra de tecido, sistema para detectar a presença ou ausência de, ou mutação, na região de cromossomo 10 humano, polipeptídeo, molécula e uso de ácido nucleico e de uma molécula. BR9611255A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US584095P 1995-10-23 1995-10-23
PCT/GB1996/002588 WO1997015686A1 (en) 1995-10-23 1996-10-22 Diagnosis of susceptibility to cancer and treatment thereof

Publications (1)

Publication Number Publication Date
BR9611255A true BR9611255A (pt) 1999-12-28

Family

ID=21718018

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9611255-7A BR9611255A (pt) 1995-10-23 1996-10-22 ácido nucleico, processos para determinar a suscetibilidade de um paciente a câncer, para diagnosticar câncer em um paciente, para prever as perspectivas relativas do surgimento particular de um câncer em um paciente, para tratar câncer e para determinar a perda de heterozigosidade em amostra de tecido, sistema para detectar a presença ou ausência de, ou mutação, na região de cromossomo 10 humano, polipeptídeo, molécula e uso de ácido nucleico e de uma molécula.

Country Status (10)

Country Link
EP (1) EP0859860A1 (pt)
JP (1) JP2000500329A (pt)
KR (1) KR19990067011A (pt)
CN (1) CN1203633A (pt)
AU (1) AU722266B2 (pt)
BR (1) BR9611255A (pt)
CA (1) CA2232241A1 (pt)
NO (1) NO981662L (pt)
NZ (1) NZ320425A (pt)
WO (1) WO1997015686A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287854B1 (en) 1996-10-22 2001-09-11 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
US6262242B1 (en) * 1997-01-30 2001-07-17 Board Of Regents, The University Of Texas System Tumor suppressor designated TS10Q23.3
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
AU8479498A (en) * 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use
AU4188499A (en) * 1998-05-14 1999-11-29 University Of Virginia Patent Foundation Isolation and use of fetal urogenital sinus expressed sequences
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
GB9903841D0 (en) 1999-02-20 1999-04-14 Imp College Innovations Ltd Diagnosis and treatment of cancer
FR2810677B1 (fr) * 2000-06-27 2004-10-01 Urogene Procede de diagnostic in vitro du cancer de la prostate et kit de mise en oeuvre
CN119061128B (zh) * 2024-11-06 2025-04-18 海南大学三亚南繁研究院 一种微卫星dna扩增引物对及二代测序方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2013430A1 (en) * 1990-03-29 1991-09-29 Michael Litt Method for identifying human subjects by analysis of genetic material
GB9307754D0 (en) * 1993-04-15 1993-06-02 Perry Robert E Diagnostic probes and therapeutic products
US5670314A (en) * 1994-02-22 1997-09-23 Regents Of The University Of California Genetic alterations that correlate with lung carcinomas
CA2170627A1 (en) * 1994-05-20 1995-11-30 Robert Bookstein A novel prostate/colon tumor suppressor gene located on human chromosome 8

Also Published As

Publication number Publication date
AU7316196A (en) 1997-05-15
NO981662L (no) 1998-06-12
NZ320425A (en) 2001-03-30
AU722266B2 (en) 2000-07-27
NO981662D0 (no) 1998-04-14
CA2232241A1 (en) 1997-05-01
WO1997015686A1 (en) 1997-05-01
EP0859860A1 (en) 1998-08-26
CN1203633A (zh) 1998-12-30
JP2000500329A (ja) 2000-01-18
KR19990067011A (ko) 1999-08-16

Similar Documents

Publication Publication Date Title
US6251586B1 (en) Epithelial protein and DNA thereof for use in early cancer detection
Caux et al. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity
JP2004524837A (ja) 悪性細胞についての、診断的メチル化ＣｐＧリッチ配列の検出
Yuan et al. Isolation of a novel gene, TSP50, by a hypomethylated DNA fragment in human breast cancer
Bonifas et al. Mutations of keratin 9 in two families with palmoplantar epidermolytic hyperkeratosis
ATE198513T1 (de) Ptpalpha-bestimmung in der tumordiagnose und - prognose
Andujar et al. p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos
CN110257525B (zh) 对肿瘤诊断具有显著性的标记物及其用途
CA2257821A1 (en) Genes from 20q13 amplicon and their uses
Pope et al. DNA damage recognition and repair by the murine MutY homologue
BR9611255A (pt) ácido nucleico, processos para determinar a suscetibilidade de um paciente a câncer, para diagnosticar câncer em um paciente, para prever as perspectivas relativas do surgimento particular de um câncer em um paciente, para tratar câncer e para determinar a perda de heterozigosidade em amostra de tecido, sistema para detectar a presença ou ausência de, ou mutação, na região de cromossomo 10 humano, polipeptídeo, molécula e uso de ácido nucleico e de uma molécula.
CA2454866A1 (en) Methods of detecting, diagnosing and treating cancer and identifying neoplastic progression
Dabholkar et al. Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2
EP0756488A4 (en) TUMOR SUPPRESSOR GENE AND METHOD FOR DETECTING CANCER
Krex et al. Physical and functional characterization of the human LGI1 gene and its possible role in glioma development
Leśniak et al. Epigenetic control of the S100A6 (calcyclin) gene expression
Wolvekamp et al. Cautionary note on the use of end-labelling DNA fragments for detection of apoptosis
Sung et al. Isolation and characterization of cDNA clones for chicken major histocompatibility complex class II molecules
US6277968B1 (en) Human uroplakin II gene and methods for detecting and classifying bladder cancer via human uroplakin genes
KR102520996B1 (ko) 간암 진단용 조성물
Polidoro et al. Isoelectric focusing of brain cortex GSH S-transferase activity in mammals: evidence that polymorphism is absent in man
Rass et al. Immunohistochemical analysis of DNA mismatch repair enzyme hMSH-2 in normal human skin and basal cell carcinomas
DE69833104D1 (de) Glaukom diagnose und behandlung
BR0115728A (pt) Análise da expressão de ácidos nucléicos kiaa e polipeptìdeos úteis no diagnóstico e tratamento de cáncer de próstata
BR0115689A (pt) Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 8A E 9A ANUIDADES.